We are a private biopharmaceutical company developing therapies for ocular disorders


Peter Widdowson, CEO

Dr. Peter Widdowson has over 30 years of drug discovery experience during which he has worked on a number of small molecule, protein and gene therapy approaches to managing disease. He has a background in researching therapies for indications as diverse as ophthalmic, neurological and psychiatric disorders, type-2 diabetes, oncology, gastrointestinal motility disorders and inflammatory conditions encompassing inflammatory bowel disease and rheumatoid arthritis.

He has held a number of senior scientific roles within Servier (Research Group Leader), AstraZeneca (Senior Scientist and Project Research Manager), Pfizer (Senior Scientist and Project Research Manager), OSI Pharmaceuticals (Director of Pharmacology) and most recently, whilst Head of Preclinical Development at Oxford BioMedica was responsible for overseeing and managing the development of three lentiviral vector gene therapies for wet age-related macular degeneration, Stargardt disease and Usher 1B syndrome which are all currently in Phase I/II clinical development. Dr. Widdowson has experience in all aspects of preclinical and early stage development from animal model proof-of-concept studies to clinical trial design and biomarker identification. Dr Widdowson holds a Bachelor of Science degree in human Physiology from Newcastle University and a PhD in Neuropharmacology from Manchester University.

Keith Martin, CSO

Prof. Martin is a Professor in the Departments of Clinical Neurosciences and Ophthalmology at the University of Cambridge and an Honorary Consultant Ophthalmologist within the National Health Service at Addenbrooke’s Hospital where he leads the Glaucoma Service. He is also Vice President and President Elect of the World Glaucoma Association, the largest glaucoma organisation in the world. Prof. Martin’s research interests include the mechanisms of retinal ganglion cell death in glaucoma and he is developing neuroprotection strategies to slow the progression of glaucomatous visual loss, and ultimately to restore vision. Keith Martin graduated in Neuroscience from Cambridge University in 1990 and from Oxford University Clinical School in 1993. He trained in General Medicine and Neurology at the Hammersmith Hospital and the National Hospital for Neurology & Neurosurgery in London and the John Radcliffe Hospital in Oxford. His Higher Specialist Training in Ophthalmology was undertaken in Cambridge before three years of Research and Clinical Fellowship Training in glaucoma with Harry Quigley at the Wilmer Eye Institute, Johns Hopkins University, Baltimore and with Prof. Peng Khaw at the Institute of Ophthalmology, UCL. His research group was the first to demonstrate that increased expression of Brain-Derived neurotrophic Factor through AAV-medicated gene therapy demonstrated a protective effect on RGC loss in a model of glaucoma.